Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 1
2012 1
2013 1
2015 2
2018 2
2020 1
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.
Russano M, Cortellini A, Giusti R, Russo A, Zoratto F, Rastelli F, Gelibter A, Chiari R, Nigro O, De Tursi M, Bracarda S, Gori S, Grossi F, Bersanelli M, Calvetti L, Di Noia V, Scartozzi M, Di Maio M, Bossi P, Falcone A, Citarella F, Pantano F, Ficorella C, Filetti M, Adamo V, Veltri E, Pergolesi F, Occhipinti MA, Nicolardi L, Tuzi A, Di Marino P, Macrini S, Inno A, Ghidini M, Buti S, Aprile G, Lai E, Audisio M, Intagliata S, Marconcini R, Brocco D, Porzio G, Piras M, Rijavec E, Simionato F, Natoli C, Tiseo M, Vincenzi B, Tonini G, Santini D. Russano M, et al. Cancer Immunol Immunother. 2022 Apr;71(4):865-874. doi: 10.1007/s00262-021-03045-9. Epub 2021 Aug 31. Cancer Immunol Immunother. 2022. PMID: 34462870 Free PMC article.
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.
Pinto C, Normanno N, Orlandi A, Fenizia F, Damato A, Maiello E, Tamburini E, Di Costanzo F, Tonini G, Bilancia D, Corsi D, Pisconti S, Ferrau F, Gori S, Daniele B, Zaniboni A, Soto Parra H, Frassinetti GL, Iaffaioli RV, Cassata A, Zampino MG, Repetto L, Calegari MA, Barone C; all the investigators of ERMES study group.. Pinto C, et al. Future Oncol. 2018 Jun;14(14):1339-1346. doi: 10.2217/fon-2017-0592. Epub 2018 May 30. Future Oncol. 2018. PMID: 29846100 Clinical Trial.
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
Rosati G, Lonardi S, Galli F, Di Bartolomeo M, Ronzoni M, Zampino MG, Banzi M, Zaniboni A, Pasini F, Bozzarelli S, Garattini SK, Ferrari D, Montesarchio V, Mambrini A, Ciuffreda L, Galli F, Pusceddu V, Carlomagno C, Bidoli P, Amoroso D, Bochicchio AM, Frassineti L, Corsi D, Bilancia D, Pastorino A, De Stefano A, Labianca R; TOSCA (Three or Six Colon Adjuvant) investigators. Rosati G, et al. Eur J Cancer. 2021 May;148:190-201. doi: 10.1016/j.ejca.2021.01.051. Epub 2021 Mar 18. Eur J Cancer. 2021. PMID: 33744715
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.
Santini D, Procopio G, Porta C, Ibrahim T, Barni S, Mazzara C, Fontana A, Berruti A, Berardi R, Vincenzi B, Ortega C, Ottaviani D, Carteni G, Lanzetta G, Virzì V, Santoni M, Silvestris N, Satolli MA, Collovà E, Russo A, Badalamenti G, Fedeli SL, Tanca FM, Adamo V, Maiello E, Sabbatini R, Felici A, Cinieri S, Tonini G, Bracarda S. Santini D, et al. PLoS One. 2013 Dec 30;8(12):e83026. doi: 10.1371/journal.pone.0083026. eCollection 2013. PLoS One. 2013. PMID: 24386138 Free PMC article.
Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.
Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G. Vincenzi B, et al. PLoS One. 2015 Jul 31;10(7):e0133488. doi: 10.1371/journal.pone.0133488. eCollection 2015. PLoS One. 2015. PMID: 26230853 Free PMC article.
12 results